Spots Global Cancer Trial Database for A Phase I Study of ECO-4601 in Patients With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I Study of ECO-4601 in Patients With Advanced Cancer
Official Title: A Phase I, Dose Finding, Pharmacokinetic, and Safety Study of Continuous IV Infusion of ECO-4601 in Patients With Advanced Cancer Including an Extension Portion to Obtain Safety Data at the Highest Tolerable Dose
Study ID: NCT00338026
Interventions
Study Description
Brief Summary: The purpose of this study was to determine the maximum tolerated dose (MTD) and the recommended dose for future studies of ECO-4601 administered as a continuous IV infusion for 14 days with 7 days recovery (21 day cycle) in patients with histologically confirmed solid tumors (high grade glioma, colorectal, lung, breast, ovarian, pancreatic and prostate). This study was also designed to determine the clinical pharmacokinetic profile, safety of multiple cycles of administration, and document the antitumor activity of ECO-4601.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hôpital Charles LeMoyne, Greenfield Park, Quebec, Canada
Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada
Contact Details
Name: Petr Kavan, MD, Ph.D.
Affiliation: Sir Mortimer B. Davis - Jewish General Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Benoît Samson, MD
Affiliation: Hôpital Charles Lemoyne
Role: PRINCIPAL_INVESTIGATOR
Name: Gerald Batist, MD
Affiliation: Sir Mortimer B. Davis - Jewish General Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
